NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-TW-21-001 from the NIH Guide for Grants and Contracts
Notice NOT-MD-21-011 from the NIH Guide for Grants and Contracts
Notice NOT-MD-21-010 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-001 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-089 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to provide continuing support for specific pathogen-free (SPF) macaque colonies previously funded under the auspices of PAR-18-669 and PAR-14-066. Breeding colonies are essential to sustain appropriate macaques for research related to Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS). Pedigree SPF macaques are free of certain viruses, which may confound the results of HIV/AIDS-related investigations or present a risk to the personnel who care for the animals. The SPF macaques are genetically characterized for major histocompatibility complex (MHC) class I types, because MHC class I genotypes have large effects on macaque immune responses to Simian Immunodeficiency Virus (SIV, which can induce AIDS in nonhuman primates (NHP)) and on human immune responses to HIV.
Funding Opportunity PAS-21-031 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
Funding Opportunity RFA-DK-20-508 from the NIH Guide for Grants and Contracts. Type 1 diabetes (T1D) is a serious and burdensome chronic disease that usually onsets in childhood or early adulthood. Recent progress in clinical trials and understanding of T1D pathogenesis and mechanisms have created opportunities to delay the onset and progression of the disease. This supplement is intended to provide resources for the design and conduct of new intervention studies in individuals at early pre-clinical stages of T1D and in individuals with new-onset T1D through the T1D TrialNet network (TrialNet). This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator of the TrialNet Coordinating Center (TNCC) that is currently supporting the research being performed by TrialNet. The TNCC provides TrialNet with scientific leadership in study design and monitoring, supports the clinical and laboratory testing for the conduct of trials, and supports systems for data collection, processing, biostatistical analyses and administrative operations.
Funding Opportunity RFA-AI-21-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.
Funding Opportunity RFA-RM-21-010 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications for the Consortium Organization and Data Coordinating Center (CODCC) of the Cellular Senescence Network (SenNet) consortium. The goal of SenNet is to identify and functionally characterize the heterogeneity of senescent cells across multiple tissues in human health, and lifespan at single-cell resolution. The CODCC will serve as the organizational hub for SenNet collecting, storing, curating, and disseminating all data, metadata, analysis and visualization tools, computational models, and aggregate data across the Network into a searchable Atlas of Cellular Senescence; ensure the utility of the database; and promote collaboration through Network engagement with the research community.
Funding Opportunity RFA-RM-21-009 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit novel analytics and technologies to identify senescent cells in human tissues This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and methods that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in mammalian tissues. The subsequent UH3 phase is to support initial validation in human tissues, optimization and scale-up, and generation of production level data. Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds.
Funding Opportunity RFA-RM-21-008 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) to work within the Cellular Senescence Network (SenNet). The goal of the SenNet consortium is to identify and functionally characterize the heterogeneity of senescent cells across multiple tissues in human health, disease, and lifespan at single-cell resolution. Through collaborative efforts, the consortium will generate a multimodal, multidimensional Atlas of senescent cells in various human tissues; develop innovative tools and technologies to identify and characterize senescent cells; and aggregate data across the Network into a searchable Atlas of Cellular Senescence, ensure the utility of the database, and promote collaboration through Network engagement with the research community. The TMCs solicited through this RFA will generate the high-resolution, high-content, multiscale biomarkers and maps of cellular senescence across the lifespan and physiological states necessary to generate the Senescence Atlas. The SenNet is focused on healthy human tissues, and work in diseased tissue or animal models is acceptable only as long as it is used to support this overall goal. TMCs will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through analyses at organ, tissue and single cell level using omics, imaging and other approaches, to data integration, analysis and interpretation.
Notice NOT-AA-20-026 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-21-017 from the NIH Guide for Grants and Contracts. This FOA seeks applications to perform single nucleus RNA sequencing (snRNA seq) and whole genome sequencing (WGS) in post-mortem brain tissue from 100 patients with PD and normal controls for the Accelerating Medicine Partnership in Parkinson's Disease (AMP PD). Applicants will be expected to have access to high quality brain tissue and perform sequencing in four separate brain regions, including some regions known to be affected by Parkinson's Disease (PD) and at least one region known to be relatively spared. It is intended that all sequencing data and any available pre-mortem clinical data will be broadly shared with the research community through the AMP PD Knowledge Portal.
Funding Opportunity RFA-DK-20-032 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.
Funding Opportunity RFA-HL-21-014 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity is to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease (CVD) among individuals with Type 1 Diabetes Mellitus (T1DM), and support the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic studies to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM. The focus of this FOA is on macrovascular disease that includes outcomes of myocardial infarction, stroke, peripheral artery disease, heart failure, cardiomyopathy, cardiac arrythmias and cardiac autonomic neuropathy and/or the study of coronary arteries, cerebral arteries, large peripheral arteries, cardiac tissue, atherosclerosis, thrombosis and lipoprotein metabolism. Research can include the effect of microvascular disease on the development of macrovascular disease, e.g., DKD, but the emphasis must be on CVD.
Notice NOT-AR-21-012 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-047 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-027 from the NIH Guide for Grants and Contracts
Notice NOT-HS-21-006 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-025 from the NIH Guide for Grants and Contracts